FORM PTC	)-1449	(modified)						Atty.	M#				Client	Ref.		. :
To: U.S. D (PW FORM	epartn I PAT-	nent of Commerce	OCT	1 4 20i	, yc35 <del>1</del>			Dkt. No.								
		/						·	037	7003-027546	3		1992	-30-	0029CP	2
INFORM. BY APPL		N DISCLOSUR	EST	<u>aten</u>	ENT			Applicant	t: Ar	nderson, et al	<b>.</b>					
								Appln. No	o.: 0	8/921,060						
					1		1			ugust 29, 19					`	
Date: Octo	ber 1	4 2003	Page	1 1	of	2	<u> </u>	Examine	r: Sc	hwadron, R.	Gro	up /	Art Ur	<u> 1:1:1</u>	644	
U.S. PATE	NT E	OCUMENTS			King.			1	<b>4</b> , 4	ion ( Kar i V		dåi.	Part III		di.	2134
Examiner		Document		Date		Name					Clas		Sub		Filing	
S		Number		MMA	YYY	(Family N	lame	of First Inv	vent	or)			Class		Date	
Initials*	-										<b>A</b>	_	-		(if approp	riate)
m1	_	5,648,267		07/19	97	Reff				. `	1005	320.1				
sia Calabo sena aspa	BR	( (22)	e.t. i		135000 F		W - 0 2 i	or the market them	J	- 07			4			
FOREIGN	PAT	ENT DOCUMEN	TS	SAZ.			Kalendari Kalendari			120	19	Eng	Ilst	ク	Translati	ion
		Document	Date		Coun	try	Inve	ntor Name	•	CHCO	* /	200	ostract 🔾		Readily Available	
	Number MM		mber MM/YYYY				Inventor Name  Cabilly, et al.					100	<i>03</i>			
											·7 160	Enc	losed	Νo	Enclose	No
√3.5	CR	0 125 023 A1	11/19	84	EP		Cabi	lly, et al.				25	200			
	DR	0 125 023 B1	11/19	84	EP		Cabilly, et al.						-0			
	ER	0 125 023 B2	03/20	02	EP		Cabilly, et al.									
V	FR	0 173 494 A2	03/19	86	EP		Morrison, et al									
	GR	<del>WO 88/04936</del>	07/10	88	WO-		Robinson, e		-							
	HR		<u> </u>													
OTHER (I	ncludi	ng in this order A	uthor,	Title,	Period	ical Name	, Dat	e, Pertiner	nt Pa	ges, etc.)		Π				П
		Adams, R.A. e	t al., Di	rect im	plantal	ion and sei	rlal tra	nsplantatio	n of	human acute						
		Adams, Richar investigation of hi									tal				٠	П
		Appelbaum, F. Hodgkin's Lymph	R., Rad	tiolabe	led Mo	nocional Ai	ntibod	ies in the T	reatr	nent of Non-				~ =		П
MI		Armitage, J.O. lymphoma treated Cancer 50:1695 (	et al., I I with c	Predict	ing the	rapeutic ou	tcome	in patients	s with	diffuse histion						
		Beulianne, G.L. et al., Preduction of functional chimaeric meuse/human antibody,  Nature 312:543 (December 1984).												$\prod$		
MI	4	Brunner, K.T. 6 51 Cr-labeled allog 14:181-189 (1968	eneic ta	uantita arget co	tive as ells <i>in</i> v	say of the l vitro; inhibiti	ytic action by	ction of imn	nune ly and	lymphoid cells d drugs, <i>Immu</i>	on nology					
		Chomczynski, P. et al., Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction, <i>Anal. Biochem. 162</i> :156-159 (1987).														
		Eary, J.F. et a 1268 (1990).	<i>l</i> . Imagi	ng and	Treate	nent of B-C	ell Ly	mphoma, J	J. Nu	Med 31/8 1	257					П
W)		Einfeld, D.A. e hydrophobic prote									а					П
		Goldenberg, D lymphomas with id (1991).									64					
4		Kaminski, M.G	. et al.,	"Radio	immur	notherapy o	f B-ce	ll lymphom	na wit	h [ <sup>131</sup> I] anti-B1	(anti-					П

Nh

11/24/2007

with Potent Fc-Dependent Biologic Activity. J. Immun. 139/10:3521-3526 (1987).  Marx, Amibodies made to order, Science 229 455 (August 1985).  Morrison, S.L. at.A., chimfer human ambody motecutes: Meuse entigen-binding demeins with human constant region domains, PNAS 91:0851-0854 (November 1984).  Morrison, Transfectomas provide novel chimeric antibodies, Science 229:1202-1207 (September 1985).  Mithro-Uses of chimaeric antibodies, Nature 312:597 (December-1984).  Neuberger, M.S. of et., A hapten-specific chimaeric ige antibody with human physiological effector function, Nature 312:597 (December-1984).  Press et al., Monoclonal antibody iff (March 1985).  Press et al., Monoclonal antibody iff (March 1985).  Press, O.W. et al., "Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support." New England Journal of Medicine 329/17: 1219-12223 (1993).  Robinson, R.D. et al., "Chimeric mouse-human entilegistics straight and interest and different anti-tumor cell biological activities." Hum. Antibod, Hybridemas 2:84-93 (1991).  Schagen et al., A genetically engineered murine/human chimeric antibody retains specifically for human Tumor-associated antityen, J. Immunol. 137:1088-1074 (1986).  Schaff, M., The synthesis, assembly, and secretion of immunoglobulin: A biochemical and genetic approach, Harvey Lectures 69:125-143 (1974).  Schulman, M. et al., A better cell line for making hybridomas secreting specific antibodies, Nature 276:289 (1978).  Srivastava, S.C., et al., Progress in research on ligands, nuclides and techniques for (30biling manoclonal antibodies with 17-1A-derived variable and human constant regions, Hybridoma 97:517 (1986).  Jan et al., A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in mouse myeloma cells, J. Immunol. 135:5554 (November 1985).  Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, J. Biol. Chem. 264(19):11282-11287 (1989).	·M	Liu, A.Y. et al., Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20	<u> </u>	1	T	Т
Morrison, S.L. et al., Chimtenc human antibody motecutes: Meuse antigen-binding demains with fluman constant region domains, PNAS 91:8851-8954 (November 1984).  -Morrison, Transfectomas provide novel chimeric antibodies, Science 229:1202-1207 (September 1985).  Milmor, Uses of chimaeric antibodies, Nature 312:597 (December 1984).  Neuberger, M.S. et al., A hapten-specific chimaeric tige antibody with Human physiological effector function, Nature 317:258 (March 1985).  Press et al., Monoclonal antibody 176 (Anti-CD20) serotherapy of human B cell lymphomas, Blood 69(2):584-591 (1987)  Press, O.W. et al., "Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support." New England Journal of Medicine 329/17: 1219-12223 (1993).  Press, O.W. et al., "Treatment of refractory non-Hedgkin's hymphoma with radiotabeted MB-T (anti-CD37) entibody. J. Clin. Onc. 7/8:1027-1036 (1989)  Robinson, R.D. et al., "Chimaric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities," Hum. Antibod. Hybridomas 2:84-93 (1991).  Schagan et al., A genetically engineered murine/human chimeric anabody retains specificily for human tumor-associated antigen, J. Immunol. 137:1066-1074 (1986).  Schaff, M., The synthesis, assembly, and secretion of immunoglobulin: A biochemical and genetic approach. Harvey Lectures 69:125-143 (1974).  Shulman, M. et al., A better cell line for making hybridomas secreting specific antibodies, Nature 276:269 (1978).  Shulman, M. et al., A better cell line for making hybridomas secreting specific antibodies, Nature 37:517 (1986).  Jan et al., A human-mouse chimeric immunoglobulin gene with a human veriable region is expressed in mouse myeloma cells, J. Immunol. 135:8584 (November 1985).  Urlaub, G. et al., Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions." Som. Cell & Mol. Gen. 120:655-566 (1986).  Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, J. Biol. Chem. 264(19):1128	(17)					
demeins with human constant region domains, PNAS 81.6651-6854 (November 1984).  Morrison, Transfectomas provide novel chimeric antibodies, Science 229-1202-1207 (September 1985).  Mitmo, Uses of chimeeric antibodies, Nature 312:597 (December 1984).  Neuberger, M.S. et al., A hapten-specific chimaeric IgE antibody with Human physiological effector function, Nature 312:597 (December 1984).  Neuberger, M.S. et al., A hapten-specific chimaeric IgE antibody with Human physiological effector function, Nature 312:597 (December 1984).  Press et al., Monoclonal antibody 175 (Anti-CD20) serotherapy of human B cell lymphomas, Bland 69(2):584-591 (1987)  Press, O.W. et al., "Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support." New England Journal of Medicine 329/17: 1219-12223 (1993).  Press, O.W. et al., "Tradiment of refractory non-Hedgkin's lymphoma with radiolabeted MB-T (anti-CD37) entibody. J. Clin. Onc. 170: 1627-1698 (1989)  Robinson, R.D. et al., "Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities," Hum. Antibod. Hybridomas 2:84-93 (1991).  Schagen et al., A genetically engineered murtherhuman chimeric antibody retains specificity for human tumor associated antigen, J. Immunol. 1971:068-1074 (1986).  Schaff, M., The synthesis, assembly, and secretion of immunoglobulin: A biochemical and genetic approach, Harvey Lectures 69:125-143 (1974).  Shulman, M. et al., A better cell line for making hybridomas secreting specific antibodies, Nature 276:269 (1978).  Shulman, M. et al., Pregress in research on ligands, nuclides and techniques for labeling menoclonal antibodies with 17-1A-derived variable and human constant regions, Hybridoma 57:517 (1986).  Jan et et, A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in wouse myeloma cells, J. Immunol. 135:8584 (November 1985).  Urlaub, G. et al., Effect of gamma rays at the dihydrofolate reduciase locus: deletions and inversions." Som. Cell & Mol. Gen.		Marx, Antibodies made to order, Science 229 455 (August 1985).				Τ
(September 1985).  Mürror, Uses of chimaenic antitodies, Nature 312:597 (December 1984).  Meuberger, M.S. et al., A hapten-specific chimaenic tgE antitody with fitiman physiological effector function, Nature 314:288 (March 1985).  Press et al., Monoclonal antibody 1F5 (Anti-CD20) serotherapy of human B cell lymphomae, Bland 69(2):584-591 (1987)  Press, O.W. et al., "Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support." New England Journal of Medicine 329/17: 1219-12223 (1993).  Press, O.W. et al., "Treatment of refractory, non-Hedgkin's lymphomae with radiolabeled MB-T (anti-CD37) entibody. J. Clin. Onc. 7/8:1627-14936 (1989)  Robinson, R.D. et al., "Chimeric mouse-human anti-carcinomae antibodies that mediate different anti-tumor cell biological activities," Hum. Antibod. Hybridemas 2:84-93 (1991).  Schagen et al., A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen, J. Immunol. 137:1086-1074 (1986).  Scharff, M., The synthesis, assembly, and secretion of immunoglobulin: A biochemical and genetic approach, Harvey Lectures 69:125-143 (1974).  Schurt, M. et al., A better cell line for making hybridomas secreting specific antibodies, Nature 276:599 (1978).  Srivastava, S.C., et al., Progress in research on ligands, nuclides and techniques for abeling menoclonal antibodies, Nucl. Med. Bio. 18(6): 569-603 (1991).  Sun, L.K. et al., Chimgric antibodies with 17-1A-derived variable and human constant ringings, Hybridoma 37:517 (1986).  Jan et al., A human-mouse chimeric immunoglobulin gene with a human veriable region is expressed in mouse myeloma cells, J. Immunol. 135:8584 (November 1985).  Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, J. Biol. Chem. 264(19):11282-11287 (1989).						Γ
Neuberger, M.S. et al., A hapten-specific chimaeric tgE antibody with fluman physiological effector function, Nature 314:288 (March 1985).  Press et al., Monoclonal antibody 1F6 (Anti-CD20) serotherapy of human B cell lymphomas, Blood 69(2):584-591 (1987)  Press, O.W. et al., "Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support." New England Journal of Medicine 329/17: 1219-12223 (1993).  Press, O.W. et al., "Treatment of refractory non-Hodgkin's lymphoma with radiolabeted MB-T (anti-CB37) entibody. J. Clim. Onc. 7/6:1627-1638 (1998)  Robinson, R.D. et al., "Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities," Hum. Antibod. Hybridomas 2:84-93 (1991).  Schagen et al., A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen, J. Immunol. 137:1068-1074 (1986).  Schaff, M., The synthesis, assembly, and secretion of immunoglobulin: A biochemical and genetic approach, Harvey Lectures 69:125-143 (1974).  Shuman, M. et al., A better cell line for making hybridomas secreting specific antibodies, Nature 276:269 (1978).  Srivastava, S.C., et al., Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies, Nucl. Med. Bio. 18(6): 689-603 (1991).  Son, L.K. et al., Chimeric antibodies with 17-1A-derived variable and human constant regions, Hybridoma 57:517 (1986).  Jan et al., A human-mouse chimeric immunoglobulin gene with a human-variable region is expressed in mouse myeloma cells, J. Immunol. 135:8564 (November 1985).  Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, J. Biol. Chem. 264(19):11282-11287 (1989).						
physiological effector function, Nature 314:288 (March 1985).  Press et al., Monoclonal antibody 1F5 (Anti-CD20) serotherapy of human B cell lymphomas, Bload 69(2):584-591 (1987)  Press, O.W. et al., "Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support." New England Journal of Medicine 329/17: 1219-12223 (1993).  Press, O.W. et al., "Treatment of refractory nen Hedgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J. Clin. Onc. 779:1927-1938 (1998)  Robinson, R.D. et al., "Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell blotogical activities," Hum. Antibod. Hybridomas 2:84-93 (1991).  Schagan et al., A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen, J. Immunol. 137:1066-1074 (1986).  Scharff, M., The synthesis, assembly, and secretion of immunoglobulin: A biochemical and genetic approach, Harvey Lectures 69:125-143 (1974).  Shulman, M. et al., A better cell line for making hybridomas secreting specific antibodies, Nature 276:269 (1978).  Srivastava, S.C., et al., Pregress in research on ligands, nuclides and techniques for labeling monoclonal antibodies, Nucl. Med. Bio. 18(6): 589-603 (1991).  Sun, L.K. et al., Chimeric antibodies with 17-1A derived variable and human constant renigs, Hybridoma 57:517 (1986).  Tan et al., A human-mouse chimeric immunoglobulin gene with a human-variable region is expressed in mouse myeloma cells, J. Immunol. 135:8564 (November 1985).  Vialub, G. et al., Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions." Som. Cell & Mol. Gen. 12/6:555-566 (1986).  Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, J. Biol. Chem. 264(19):11282-11287 (1989).		Münro, Uses of chimaeric antibodies, Nature 312:597 (December 1984).				T
Imphomas, Blood 69(2):584-591 (1987)   Press, O.W. et al., "Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support." New England Journal of Medicine 329/17: 1219-12223 (1993).   Rress, O.W. et al., "Treatment of refractory non-Hodgkin's lymphoma with radiolabeted MB-1 (anti-CD37) antibody. J. Clin. Onc. 7/8:1027-1036 (1989)   Robinson, R.D. et al., "Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities," Hum. Antibod. Hyhdidomas 2:84-93 (1991).   Schagan et al., A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen, J. Immunol. 137:1068-1074 (1986).   Scharff, M., The synthesis, assembly, and secretion of immunoglobulin: A biochemical and genetic approach, Harvey Lectures 69:125-143 (1974).   Shulman, M. et al., A better cell line for making hybridomas secreting specific antibodies, Nature 276:269 (1978).   Shuman, M. et al., A better cell line for making hybridomas secreting specific antibodies, Nature 276:269 (1978).   Shumanan of the shuman secretion of immunoglobulin gene with a human constant regions, Hybridoma 57:517 (1986).   Jan et et, A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in mouse myeloma cells, J. Immunol. 135:8564 (November 1985).   Williams, G. et al., Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions." Som. Cell & Mol. Gen. 12/6:555-566 (1986).   Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, J. Biol. Chem. 264(19):11282-11287 (1989).		Neuberger, M.S. et al., A hapten-specific chimaeric IgE antibody with human physiological effector function, Nature 314:268 (March 1985).				T
bone marrow support." New England Journal of Medicine 329/17: 1219-12223 (1993).  Rress, O.W. et al., "Treatment of refractory non Hedgkin's lymphoma with radiotabeted MB-T (anti-cD37) antibody, J. Clin. Onc. 7/8:1027-1036 (1989)  Robinsen, R.D. et al., "Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities," Hum. Antibod. Hybridomas 2:84-93 (1991).  Schagan et al., A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen, J. Immunol. 137:1066-1074 (1986).  Scharff, M., The synthesis, assembly, and secretion of immunoglobulin: A biochemical and genetic approach, Harvey Lectures 69:125-143 (1974).  Shulman, M. et al., A better cell line for making hybridomas secreting specific antibodies, Nature 276:269 (1978).  Srivastava, S.C., et al., Progress in research on ligands, nuclides and techniques for labeling menoclonal antibodies, Nucl. Med. Bio. 18(6): 589-603 (1991).  Sun, L.K. et al., Chimeric antibodies with 17-1A-derived variable and human constant regions, Hybridoma 57:517 (1986).  Jan et al., A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in wouse myeloma cells, J. Immunol. 135:8564 (November 1985).  Urlaub, G. et al., Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions." Som. Cell & Mol. Gen. 12/6:555-566 (1986).  Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, J. Biol. Chem. 264(19):11282-11287 (1989).		Press et al., Monoclonal antibody 1F5 (Anti-CD20) serotherapy of human B cell lymphomas, Blood 69(2):584-591 (1987)				
Robinson, R.D. et al., "Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell blological activities," Hum. Antibod. Hybridomas 2:84-93 (1991).  Schagen et al., A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen, J. Immunol. 137:1668-1074 (1986).  Scharff, M., The synthesis, assembly, and secretion of immunoglobulin: A biochemical and genetic approach, Harvey Lectures 69:125-143 (1974).  Shulman, M. et al., A better cell line for making hybridomas secreting specific antibodies, Nature 276:269 (1978).  Srivastava, S.C., et al., Pregress in research on ligands, nuclides and techniques for labeling menoclonal antibodies with 17-1A-derived variable and human constant regions, Hybridoma 57:517 (1986).  Jan et al., A human-mouse chimeric immunoglobulin gene with a human-variable region is expressed in mouse myeloma cells, J. Immunol. 135:8564 (November 1985).  Urlaub, G. et al., Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions." Som. Cell & Mol. Gen. 12/6:555-566 (1986).  Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, J. Biol. Chem. 264(19):11282-11287 (1989).	MI	Press, O.W. et al., "Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support." New England Journal of Medicine 329/17: 1219-12223 (1993).				
different anti-tumor cell biological activities," Hum. Antibod. Hybridomas 2:84-93 (1991).  Schagen et al., A genetically engineered murine/numan chimeric antibody retains specificity for human tumor-associated antigen, J. Immunol. 137:1068-1074 (1986).  Scharff, M., The synthesis, assembly, and secretion of immunoglobulin: A biochemical and genetic approach, Harvey Lectures 69:125-143 (1974).  Shulman, M. et al., A better cell line for making hybridomas secreting specific antibodies, Nature 276:269 (1978).  Srivastava, S.C., et al., Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies, Nucl. Med. Bio. 18(6): 589-603 (1991).  Sun, L.K. et al., Chimeric antibodies with 17-1A-derived variable and human constant repigns, Hybridoma 5/1:517 (1986).  Tan et el., A human-mouse chimeric immunoglobulin gene with a human-variable region is expressed in resules myeloma cells, J. Immunol. 135:8564 (November 1985).  Urlaub, G. et al., Effect of gamma rays at the dihydrofolate reductiase locus: deletions and inversions." Som. Cell & Mol. Gen. 12/6:555-566 (1986).  Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, J. Biol. Chem. 264(19):11282-11287 (1989).		Rress, O.W. et al., "Treatment of refractory non Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody, J. Clin. Onc. 7/8:1027-1038 (1989)				
Specificity for human tumor-associated antigen, <i>J. Immunol.</i> 137:1068-1074 (1986).  Scharff, M., The synthesis, assembly, and secretion of immunoglobulin: A biochemical and genetic approach, <i>Harvey Lectures</i> 69:125-143 (1974).  Shulman, M. et al., A better cell line for making hybridomas secreting specific antibodies, <i>Nature</i> 276:269 (1978).  Srivastava, S.C., et al., Progress in research on ligands, nuclides and techniques for labeling menoclonal antibodies, <i>Nucl. Med. Bio.</i> 18(6): 589-603 (1991).  Sun, L.K. et al., Chimeric antibodies with 17-1A-derived variable and human constant regions, <i>Hybridoma</i> 57:517 (1986).  Tan et al., A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in mouse myeloma cells, <i>J. Immunol.</i> 135:8564 (November 1985).  Urlaub, G. et al., Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions." <i>Som. Cell &amp; Mol. Gen.</i> 12/6:555-566 (1986).  Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, <i>J. Biol. Chem.</i> 264(19):11282-11287 (1989).	Nw/0					Γ
Scharff, M., The synthesis, assembly, and secretion of immunoglobulin: A biochemical and genetic approach, Harvey Lectures 69:125-143 (1974).  Shulman, M. et al., A better cell line for making hybridomas secreting specific antibodies, Nature 276:269 (1978).  Srivastava, S.C., et al., Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies, Nucl. Med. Bio. 18(6): 589-603 (1991).  Sun, L.K. et al., Chimeric antibodies with 17-1A-derived variable and human constant repions, Hybridoma 5/1:517 (1986).  Tan et el., A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in mouse myeloma cells, J. Immunol. 135:8564 (November 1985).  Urlaub, G. et al., Effect of gamma rays at the dihydrofolate reduciase locus: deletions and inversions." Som. Cell & Mol. Gen. 12/6:555-566 (1986).  Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, J. Biol. Chem. 264(19):11282-11287 (1989).		Sahagan et al., A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen, J. Immunol. 137:1086-1074 (1986).				Γ
Shulman, M. et al., A better cell line for making hybridomas secreting specific antibodies, Nature 276:269 (1978).  Srivastava, S.C., et al., Progress in research on ligands, nuclides and techniques for labeling menoclonal antibodies, Nucl. Med. Bio. 18(6): 589-603 (1991).  Sun, L.K. et al., Chimeric antibodies with 17-1A-derived variable and human constant repions, Hybridoma 5/1:517 (1986).  Tan et al., A human-mouse chimeric immunoglobulin-gene with a human variable region is expressed in mouse myeloma cells, J. Immunol. 135:8564 (November 1985).  Urlaub, G. et al., Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions." Som. Cell & Mol. Gen. 12/6:555-566 (1986).  Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, J. Biol. Chem. 264(19):11282-11287 (1989).	KG)	Scharff, M., The synthesis, assembly, and secretion of immunoglobulin: A biochemical				Г
Sun, L.K. et al., Chimeric antibodies with 17-1A-derived variable and human constant repions, Hybridoma 5/1:517 (1986).    Tan et al., A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in wouse myeloma cells, J. Immunol. 135:8564 (November 1985).    Urlaub, G. et al., Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions." Som. Cell & Mol. Gen. 12/6:555-566 (1986).    Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, J. Biol. Chem. 264(19):11282-11287 (1989).	VB1	Shulman, M. et al., A better cell line for making hybridomas secreting specific				
Tan et et., A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in mouse myeloma cells, J. Immunol. 135:8564 (November 1985).  Urlaub, G. et al., Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions." Som. Cell & Mol. Gen. 12/6:555-566 (1986).  Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, J. Biol. Chem. 264(19):11282-11287 (1989).		Srivastava, S.C., et al., Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies, <i>Nucl. Med. Bio.</i> 18(6): 589-603 (1991).				
Urlaub, G. et al., Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions." Som. Cell & Mol. Gen. 12/6:555-566 (1986).  Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, J. Biol. Chem. 264(19):11282-11287 (1989).  Date Considered:	*	Sun, L.K. et al., Chimeric antibodies with 17-1A-derived variable and human constant regions, Hybridoma 5/1:517 (1986).				
Urlaub, G. et al., Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions." Som. Cell & Mol. Gen. 12/6:555-566 (1986).  Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, J. Biol. Chem. 264(19):11282-11287 (1989).  Date Considered:		Tan et et., A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in mouse myeloma cells, J. Immunol. 135:8564 (November 1985).	~ .		·	
Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, J. Biol. Chem. 264(19):11282-11287 (1989).  Date Considered: 11124727	,my	Urlaub, G. et al., Effect of gamma rays at the dinvergolate reductase logue: deletions	به کیند د (عور س			
Date Considered: 11/2 4/24727	m/	Valentine, M.A. et al., Phosphorylation of the CD20 phosphorrotein in resting R				
CAMINER: Initial if citation considered, whether or not election is in and the considered.	xaminer			<u>_</u>		
	EXAMINER:	Initial if citation considered, whether or not citation is in conference with ARP 2000	1100	_/_		_

not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM FOOTON	. Depar	tment T-144	of Commerce 9)	DE O	-,	OFFICE LE			Atty. Dkt. No.	M#		Client Ref.			
			٨ /		- 5			•	l	0275463		1992-30	-00	29CP2	
INFOR			ISCLOSUR	E STO		ENT			Applicant	: ANDERSON	et al.				
									Appin. No	o.: 08/921,060		*			
ä										te: August 29,	1997				
Date: [	Decem	ber 3,	2003	Page	1	of	1		1	r: R. Schwadro		up Art Uni	t: ′	1644	
U.S. PA	TENT	DOC	UMENTS												
Examiner's Initials*			Document Number		Date MM/	·····	Nam (Fan	e nily Name	of First In	ventor)	Class	Sub Class		Filing Date	
	m	AR	6,183,744 B1		02/20		+	DENBER			_	1			
	W	BR	6,306,393 B1		10/20	001	GOL	DENBER	3	<del></del>		-			
		CR	,												
		DR					<u> </u>								
ļ		ER					<u> </u>							 	
<u> </u>	<u></u>	FR								<del></del>	<u> </u>		-,		
FORE	GN PA	TENT	DOCUMENT	1		1.						7			
			Document Number	Date MM/Y	YYY	Coun	itry	Inventor	Name			English Abstract		Translatio Readily Available	n
		GR													
		HR													
		IR		ļ	·										
		JR				<u> </u>							<u> </u>		
		KR				-		ļ					L		
	<u> </u>	LR		<u> </u>		<u> </u>		<u> </u>				1			
OTHER	(M)	MR		-I MB-	1 Antil					ell Lymphoma w onjugates, and					
			B-Cell Lymph 1051.	oma V	Vith 13	31-I MI	B-1 A	ntibody," 1	990, <i>Proc</i>	Marrow Ablative eedings of ASC	O, Vol. 9	9, p. 271, <i>i</i>	Abs	stract No	f
		OR ——	Wahl, et al., " Journal of Nu	Radioi <i>clear I</i>	mmur <i>ledici</i>	nothera ne: Pro	apy of	B-Cell Ly lings of the	mphoma v 37 <sup>th</sup> <i>Ann</i>	vith I131 MB-1 I <i>ual Meeting</i> , p.	Monocloi 852, Abs	nal Antibo stract No.	dy, 62:	" <i>The</i> 2.	
			Kaminski, et a Lymphoma," Abstract No. 6	1990, $\lambda$	ase I Antibo	Trial R ody Imr	tesult:	s of 131-I conjugates	MB-1 Anti s, and Rac	body Radioimm diopharmaceutio	unothera als, Vol.	apy (RAIT 4, No. 1,	) of p. 3	B-Cell 36,	
		QR	Kaminski, et a Lymphoma,"	al., "Ph 1990, <i>i</i>	ase I Blood,	Evalua Vol. 7	ation o	of 131-I Mi . 10, p. 35	3-1 Antibo 5a, Abstra	dy Radioimmur act No. 1409.	otherapy	y (RIT) of	B-(	Cell	
	4	RR	Kaminski, et a	al., "lm	aging	, Dosir	netry,	and Radi	oimmunot	herapy With lod					
		SR													
		TR												<del> </del>	
		UR													
Examine	er (	1	1		<u> </u>				Date Con	sidered: \\ \2	4 /2	אמ			
*EXAM		Initia	al if citation con	sidered	l, whet	her or i	not cit	ation is in c	onformanc	e with MPEP § 60			h c	itation if r	ot

									1 '	M#		Client Ref.					
To: U.S. Department of Commerce								Dkt. No.	ŀ								
(PW FORM PAT-1449) Patent and Trademark Office																	
Patent and Trademark Office									0275463		1992-30-	-00	29CP2				
INFORMATION DISCLOSURE STATEMENT									Applicant	ANDERSON	et al	1.002.00		2001 2			
BY APPLICANT										,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,							
( MAR 1 8 2004 E)										Appln. No.: 08/921,060							
MAK   E										Filing Date: August 29, 1997							
Date: N	March 18	<u>, 2d</u>	(B)	age	1	of	Examiner	: Schwadron, F	R. Grou	ıp Art Uni	t: 1	644					
U.S. PA	TENT D	OC	UMENTAGE HIT						-								
Examiners			Document		Date		Name				Class	Sub		Filing			
Initials*			Number		MM/Y	$\gamma \gamma \gamma$	(Fam	ily Name	of First Inv	entor)		Class		Date			
	,	AR-	5,595,7 <del>21</del>		01/19	97	KAM	INSKL									
MS		BR	5,439,665		08/19	95	HAN	SEN									
MI		CR	RE 38,008		02/20	03	ABR	AMS			)	-	177				
	~	DR-	<del>5,736,</del> 137		04/18	98	AND	ERSON									
V35		ER	5,776,456		07/19	98	AND	ERSON			_						
		FR	5,843,439		12/19	98	AND	ERSON			-						
		GR	6,399,061		06/20	02	ANDERSON					_					
4		HR	6,682,734	01/20	04	AND	ERSON										
FOREIGN PATENT DOCUMENTS																	
			Document Date Coun					try Inventor Name				English		Translation			
			Number MM/YYYY								Abstract		Readily Available				
		IR	WO 94/11026	05/1	994	PCT	ANDERSON					<del>                                     </del>	7	Available	П		
		JR															
		KR										1	·				
		LR		<b></b>								†	$\vdash$		⇈		
		MR	· · · · · · · · · · · · · · · · · · ·	<u> </u>		<u> </u>							_		$\vdash$		
OTHER	<u> </u>			<u>L</u>		<u> </u>		<u> </u>				<u></u>	<del></del>	l	<u> —                                   </u>		
		NR	Grosspard M.L	et a	st~"M	anacta	ne lefi	atibody-ba	sed theres	ies of lenteris	and lyn	anhoma "	Blc	od 100°			
•			80:863-878.							*********					<del></del>		
*	117		Tedder T.F., et activation of hu	ıman	B lym	phocyt	es," E	ur J Imm	unol, 1986	, 16(8):881-87.				not			
*	M	PR	Tedder T.F., et	antige	n, hor	nologo	ous to	the huma	in B1 (CD2	oding a new mo (0) antigen, and	ouse B ly I localiza	mphocyte	) 9 GE	ene to			
		QR	chromosome 1	9, J	<i>iminu</i>	noi, 19	00, 14	41(12):43	58-94.	<del></del>		· · · · · · · · · · · · · · · · · · ·	—				
		RR		· · ·		•							—				
										, tie							
		SR				· · · · · · · · · · · · · · · · · · ·											
		TR															
	1	UR															
Examine	er .	V	1 /						Date Cons	sidered:	1/2-4	1200)					
*EXAMI	NER:	Initi	al if citation cons	idered	, whet	her or r	not cita	ation is in c	onformance					itation if	not		
1			ot considered In										, •		•		

To: U.S. (PW FO	TO-1449 (mod Department o RM PAT-1449) nd Trademark	f Commerce		MA	Y 2 6 ;	3	LIGE AF	Atty. Dkt. No.	M#		Client Ref.			
				PART &			0275463		1992-30-	00:	29CP2			
	MATION DIS	SCLOSUR	E STA	TEM	ENTE	Applicant: ANDERSON et al.								
						Appln. No	o.: 08/921,060	)						
								Filing Da	te: August 29	. 1997	<del></del>			
Date: N	1ay 26, 2004		Page	1	of	1	7		r: R. Schwadi		up Art Unit	t: 1	644	
U.S. PA	TENT DOCU	MENTS				_	,						AN BOOK A	
Examiner's		Document		Date		Nam	ne		Cla				Filing	
Initials*		Number		MMA	<b>/</b>	(Far	nily Name	of First In	ventor)		Class		Date	
	AR													
	BR			ļ		<u> </u>								
	CR	ļ				<u> </u>				<del></del>	ļ			
	DR	<u> </u>		ļ	·····	<b> </b>								
	ER	<u> </u>		<u> </u>		<u> </u>	· · · · · · · · · · · · · · · · · · ·				<del> </del>			
	FR	1				├	· · · · · · · · · · · · · · · · · · ·				<u> </u>			
	GR	<del>                                     </del>		ļ		├	<del></del>		<del></del>		1	_		
5055	HR				·····	Ц					<u> </u>			
FOREIC	ON PATENT I	Document	<del></del>		TC		Immantan	None			7	i	l <del>-</del>	
		Number	MM/Y	YYY	Coun	ury	Inventor	name			English Abstract		Translati Readily Available	
	IR													
	JR				ļ								-	
	KR				ļ		ļ						····	
	LR		ļ		ļ		<del> </del>							$\sqcup$
	MR	-	ļ			<del></del>	<del> </del>							$\perp$
	NR		ļ		ļ							Ш		+
	OR PR	<u> </u>	ļ		<del> </del>		<del> </del>					$\vdash$		$\vdash$
OTUED		<u>l</u>	<u> </u>											
OTHER		Idea Dhama			0	- 0-		N= 04 400	7.150.45			_		
VP3 )	QR	2003).							37-IEG [Doc. N					4,
WH	RR	Biogen Ideo 2004).	v. Co	rixa C	<i>orp.</i> , C	ase	No. 01-16 	37-IEG [Do	oc. Nos. 635, 6	662, 486]	(S.D. Cal.	Jar ——	n. 22,	
	SR	ļ									-		·	
-	TR	<u> </u>	·											
	UR													
	VR	ļ												
	WR													
	XR								<u>-</u>					
	YR													
	ZR		<del></del>	<del></del>							<del></del>		· · · · · · · ·	_
	AAR								<u></u>		<del></del>			_
Examine		<u> </u>	)		····			Date Con	sidered:	1 1-				
		<u>-                                    </u>		<u> </u>				<u></u>	U	1/24/2				
*EXAMII	NER: Initial mance and not	if citation con	sidered	, whet	her or r	not cit	ation is in o	conformance	e with MPEP §	609. Draw	line throug	h c	itation if	not

30398286v1